中国临床药理学杂志2013，Vol.29Issue(4)：243-245,3.
奥沙利铂或伊立替康联合卡培他滨治疗晚期结直肠癌的临床研究
Clinical study of oxaliplatin or irinotecan plus capecitabine in the treatment of advanced colorectal cancer
摘要
Abstract
Objective To evaluate the clinical effect of chemotherapy regimen with Oxaliplatin or Irinotecan plus Capecitabine in the treatment of advanced colorectal cancer. Methods One hundred and twelve patients with advanced colorectal cancer who received oxaliplatin plus capecitabine or Irinotecan plus capecitabine were included in this study. The chemotherapy regimen was; oxaliplatin 130 mg ? m-2 ivgtt d 1, Irinotecan 180 mg ? m-2 ivgtt d1 and capecitabine 1250 mg ? m-2po d 1 -14 with 21 days per cycle. Results In the L - OHP + CAP group the o-verall response rate(ORR) was 27. 1% (12/48) and the median progression free survival time (PFS) was 6. 2 months. In the CPT -11+ CAP group the overall response rate(ORR) was 25. 0% (10/40) and the median progression free survival lime was 7. 1 months . There was no statistical difference between the two groups in ORR and median PFS (P = 1. 00; HR = 1. 28,95% CI:0. 81 ~ 2. 01). The patients in CPT - 11 + CAP group experienced higher Ⅲ,Ⅳ diarrhea compared with L - OHP + CAP guoup(27. 5% vs 2. 1% ,P =0. 002). In the contrary, the rate of Ⅲ , Ⅳ neurotoxicity in the group CPT - 11 + CAP was lower compared with L - OHP + CAP group (2. 5% vs 22. 9% , P =0. 018). Conclusion The therapeutic effects of irinotecan or ox-aliplatin combined with capecitabine in the treatment of advanced colorectal cancer are good and comparable. The most common toxicities were gastrointestinal reaction peripheral neuropathy and myelosuppression in the two groups and their toxicities are tolerable.关键词
晚期结直肠癌/奥沙利铂/卡培他滨/伊立替康Key words
advanced colorectal cancer/oxaliplatin/capecitabine/irinotecan分类
医药卫生引用本文复制引用
刘慧燕,张斌..奥沙利铂或伊立替康联合卡培他滨治疗晚期结直肠癌的临床研究[J].中国临床药理学杂志,2013,29(4):243-245,3.
